Decision: Favourable

Decisions Table

Study Title:

A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022)

  • NREC Code:

    22-NREC-CT-010

  • Decision:

    Favourable

  • Meeting Date:

    26/01/2022

  • Study Type:

    CT application

  • Principal Investigator:

    Professor Ray McDermott

  • Sponsor:

    MSD

Scroll to Top